Mustang Bio is a biotechnology business based in the US. Mustang Bio shares (MBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.21 – a decrease of 8.45% over the previous week. Mustang Bio employs 80 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.21 |
|---|---|
| 52-week range | $0.13 - $1.73 |
| 50-day moving average | $0.25 |
| 200-day moving average | $0.52 |
| Wall St. target price | $10.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.33 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.209 from 2024-11-20
| 1 week (2024-11-15) | -8.45% |
|---|---|
| 1 month (2024-10-22) | -25.91% |
| 3 months (2024-08-22) | -44.87% |
| 6 months (2024-05-22) | -12.92% |
| 1 year (2023-11-22) | -86.60% |
|---|---|
| 2 years (2022-11-22) | -97.19% |
| 3 years (2021-11-22) | 31.65 |
| 5 years (2019-11-21) | 42.45 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -96.52% |
| Return on equity TTM | -1191.31% |
| Profit margin | 0% |
| Book value | $-0.94 |
| Market Capitalization | $8.8 million |
TTM: trailing 12 months
We're not expecting Mustang Bio to pay a dividend over the next 12 months.
Mustang Bio's shares were split on a 1:15 basis on 3 April 2023 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Mustang Bio shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Mustang Bio shares which in turn could have impacted Mustang Bio's share price.
Over the last 12 months, Mustang Bio's shares have ranged in value from as little as $0.1281 up to $1.7277. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mustang Bio's is 1.923. This would suggest that Mustang Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Mustang Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.